# Phase Ⅲ Randomized Trial in Postoperative Hepatocellular Carcinoma

> **NCT00149565** · PHASE3 · COMPLETED · sponsor: **National Health Research Institutes, Taiwan** · enrollment: 268 (—)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** IFN-α2b

## Key facts

- **NCT ID:** NCT00149565
- **Lead sponsor:** National Health Research Institutes, Taiwan
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1997-10
- **Primary completion:** —
- **Final completion:** 2005-07
- **Target enrollment:** 268 (—)
- **Last updated:** 2005-12-16

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00149565

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00149565, "Phase Ⅲ Randomized Trial in Postoperative Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00149565. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*